ARWR was up 7.29% earlier and is still up 2.92% at present on volume of > 341Ks, which is only 1/4 its ADV.
bigcharts.marketwatch.com
The stock has closed its latest UG of May7 and it is trying to bounce up from it support at the $1.30 level to test the resistance at $1.50 <g>
bigcharts.marketwatch.com
It had some news today, but not related to Calando or other of its medical subsidiaries.<g>
The news were related to another of its subsidiaries, Unidym.
It announced that it has entered an agreement with global glass manufacturer, Guardian Industries, to develop carbon coated glass products for touch screen devices and other applications.
The companies initially plan to jointly market the coated glass products to customers in the touch panel industry.
In the manufacturing phase, Unidym plans to supply electronic inks to Guardian for the manufacture of coated glass.
ARWR's Unidym subsidiary is a leader in carbon nanotube-based transparent, conductive films for the electronics industry.
ARWR's Calando subsidiary is developing new targeted, siRNA-containing therapeutics using its three part RNAi/Oligonucleotide Nanoparticle Delivery (RONDEL) technology, the foundation of which is the cyclodextrin-containing polymer.
"Naked" siRNA is degraded and destroyed by nucleases in the bloodstream and is not taken up by cells. It also causes harmful immune reactions.
With Calando's RONDEL system, siRNA is protected by the cyclodextrin-containing polymers and thus can reach its destination and perform its intended job.
By encapsulating the siRNA, RONDEL also protects the body from the immune reactions caused by naked siRNA.
ARWR was able to trim its loss significantly for 4th time on a roll, in the 2ndQ.<g>
As mentioned, the ACTAY is $9 but that is only one "analyst" opinion.
And I will just keep my target at $3 for a possible 100% gain from present levels. <g>
bigcharts.marketwatch.com
Bernard |
